-- EUROPE RESEARCH ROUNDUP-ASML Holding, Hikma Pharmaceuticals 
-- 
-- Thu Jul 17, 2014 02:04AM EDT
-- None



July 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ASML Holding and Hikma Pharmaceuticals, on Thursday.

HIGHLIGHTS * ASML <ASML.AS>: S&P Capital IQ cuts to hold from buy  * Hikma Pharmaceuticals <HIK.L>: UBS raises to buy from neutral  * Generali <GASI.MI>: JP Morgan assumes coverage with overweight ratingFollowing is a summary of research actions on European companies reported by Reuters on Thursday. Stock entries are in alphabetical order.   * ASML <ASML.AS>: Cowen cuts price target to 75 euros from 80 euros; rating outperform * ASML <ASML.AS>: Credit Suisse raises price taret to 64 euros from 55 euros; rating neutral * ASML <ASML.AS>: S&P Capital IQ cuts to hold from buy  * ASML <ASML.AS>: S&P Capital IQ cuts price target to 70 euros from 74 euros * Elisa <ELI1V.HE>: Barclays raises target to 18 euros from 16.50 euros; rating underweight  * Generali <GASI.MI>: JP Morgan assumes coverage with overweight rating * Hikma Pharmaceuticals <HIK.L>: UBS raises to buy from neutral  * Hikma Pharmaceuticals <HIK.L>: UBS raises target price to 2000p from 1700p * Moncler <MONC.MI>: Nomura raises to buy from neutral rating * OneSavings Bank <OSBO.L>: Barclays starts with an overweight; target price 220p  * Symrise AG <SY1G.DE>: DZ Bank raises target to 46.00 euros from 40 euros; rating buy